alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Keep distorting as you are good at that. I provided the official start sites as shown by the link to the clinical trial link and you can't handle the truth. My timeline for when the trial officially commenced to the estimated completion date is accurate. Your timeline isn't.
Oops, I thought the Q2 earnings report was this upcoming Monday but it was a week later.
ed, consider the source when dealing with jake. The pediatric trial began April 26, 2022 and is estimated to be completed in December 2023. Apparently, times runs differently on planet jake as April 26 2022 is 3 years ago on his world.
https://classic.clinicaltrials.gov/ct2/show/NCT04816721
The EDP-938 trial for high risk adults began November 29th, 2022 and is estimated to be completed April 2024.
https://classic.clinicaltrials.gov/ct2/show/NCT05568706
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-initiates-phase-2b-clinical-study-edp-938
A good post for ENTA longs to read. The post is by Lishur and was on the ENTA board.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172383118
Thanks for making it clear you have no reasons for saying CD approval is already baked in the stock price or for raising the idea the label in the CD indication could be very narrow.
Not sure why you feel I am being argumentative by asking you for reasons why you made some comments. I wanted information as to why you came to those views and you refuse to provide them, rather resort to deflecting and to attack me.
This may be the last week where IMGN ever sells below $20/share.
Will wonders never cease! ENTA is up for the 3rd day in a row and closed over $22. Still a long, long way to go but it feels nice to see some positive sentiment.
Happy Independence Day! Well, it isn't July 4th yet but I took today off to give myself a 4 day weekend. :)
Will wonders never cease! ENTA is up for the 3rd day in a row and closed over $22. Still a long, long way to go but it feels nice to see some positive sentiment.
Happy Independence Day!
One can never pick a bottom but regardless of what the broader market is doing, the fact remains that EDP-235 phase 2 data was quite good. I continue to buy in small amounts and have now increased my shares by 33% since the phase 2 data release. The views of the general public on ENTA are meaningless to me. Some apparently “think” deals can be worked out in a matter of weeks, which is nonsense.
With ENTA stock continuing to take a beating, I thought I would explain why I remain bullish and a buyer.
The EDP-235 data was quite good. It showed a good safety profile, showed a statistically significant improvement in symptoms and reducing their duration, in a highly vaccinated low risk population that had mostly been previously infected. In stark contrast, Paxlovid failed to do that in an similar low risk population, but one in which most were not yet vaccinated or infected. Despite this effectiveness in improving symptoms, the knock that drove ENTA down was the lack of viral reduction in nasal swabs, even though nasal swabs isn't a metric for approval and Remdesivir didn't do that either yet got FDA approval.
That left the conundrum of why EDP-235 showed robust anti-viral effects with regards to symptoms but not in nasal viral swabs. The anomaly was a rapid decreases nasal swab viral levels in the control group, possibly due to previous infection with Covid generating strong IgM responses. That would explain the rapid clearance in mucosal membranes in controls. ENTA looked closely and saw that if they examined patients who hadn't been previously infected, those without anti-nucleocapsid antibodies, there was indeed a robust viral reduction with EDP-235. Given that the vast majority in the EDP-235 phase 2 trial had been previously infected, that would explain why no difference was seen. The general population doesn't care but prospective partners will be assured. I know I am.
Rwwine, I am never surprised at shortsightedness and fear driving a stock down, or for that matter the stock market.
Most Biotech stocks took a beating today. Did they all have bad news? Obviously not.
I have a lot of confidence in ENTA given how impressive the EDP-235 phase 2 trial data was.